with medium chain lengths at positions 1 and 2 gave an improved selective index (SI). INK-3, with 12 and 8 carbons and INK-15, with 10 and 12 carbons were among the most selective when evaluated in CEM-SS cells. INK-14, a lipid-AZT conjugate where AZT replaced the choline in PC lipid INK-3, gave the highest SI of >1250 against both infectious wt HIV-1 replication in CEM-SS cells and a clinical isolate in peripheral blood leukocytes. Notably, the PC lipid compounds INK-3 and INK-15, but not the lipid-AZT conjugate INK-14, were potent inhibitors of matched pairs of AZT-sensitive and AZT-resistant HIV-1 clinical isolates. INK-3 also inhibited replication of HIV-2 and TIBO-resistant HIV-1, and inhibited HIV-1mediated fusogenic activity by 78, 41 and 9% in a dose-dependent manner. The TC 50 for mouse bone marrow cells was >100 µg/ml for INK-3 compared to 9.15-14.17 µg/ml for CP-51 and 0.142-0.259 µg/ml for AZT. These data suggest that optimum PC lipid compounds are significantly less toxic than AZT and have high potential as novel therapeutic agents for AIDS.
Our laboratories first reported on two novel classes of complex synthetic lipids (alkylamidopropyl or alkylthioglycerol phosphocholines and phosphate ester-linked lipid-AZT conjugates) that have selective and potent activity against infectious human immunodeficiency virus (HIV) replication and pathogenesis in vitro. These compounds have a unique site of action involving alteration of HIV gp160/gp120 activity and production of defective virus particles (Kucera et al., 1990a,b; Meyer et al., 1991; Piantadosi et al., 1991; Krugner-Higby et al., 1995) . A thiolipid-nucleotide conjugate (BM21-1290) has recently been introduced into Phase I/II tolerability and efficacy trials in ARC/AIDS patients by Boehringer Mannheim (Herrmann DBJ, Schleger C & Opitz HG; Antiretroviral activity of the novel candidate anti-AIDS drug BM21.1290 in the Friend-virus leukemia system in vivo; VIth German AIDS Congress, October 24-26 1997, Munich, Germany, Abstract V160; Herrmann DBJ, Opitz HG & Kucera LS; BM21-1290: evaluation of the antiretroviral activity of a new anti-AIDS drug in-vivo. IVth Conference on Retroviruses and Opportunistic Infections, January 22-26 1997, Washington, DC, USA, Abstract p92) . Among the reported alkylamidopropyl phosphocholine (PC lipid) analogues synthesized and tested for anti-HIV-1 activity, the most selective was compound CP-51, 1-octadecanamido-2-ethoxypropyl-3-phosphocholine (Kucera et al., 1990a) . In order to extend these observations, we synthesized a series of CP-51 analogues to In vitro evaluation and characterization of newly designed alkylamidophospholipid analogues as anti-human immunodeficiency virus type 1 agents Introduction ©1998 International Medical Press 0956-3202/98/$17.00 evaluate their structure-activity relationships and thus to optimize the PC lipid compound for future evaluation as a potential therapeutic agent for AIDS. Results of this investigation indicated that among the PC lipid compounds tested in CEM-SS cells, compounds INK-3 and INK-15 with intermediate hydrocarbon chain lengths of 12 and 10, respectively, at position 1, and of 8 and 12, respectively, at position 2, gave the highest selectivity index (SI) against infectious HIV-1 replication. Selected PC lipid compounds were active against AZT-resistant clinical isolates, TIBO-resistant HIV-1 and wild-type HIV-2, inhibited HIV-1 fusogenic activity, and were less toxic to mouse bone marrow cells compared to AZT. Based on these interesting results, optimum PC lipid compounds may have great potential as novel therapeutic agents for AIDS, either alone or in combination therapy.
Materials and Methods: Chemistry
All chemicals were used as provided by the supplier without further purification unless otherwise indicated. AZT was obtained from Boehringer Mannheim (Mannheim, Germany). Column chromatography was performed with silica gel 60 (230-400 or 70-230 mesh). Melting points were obtained on a Hoover Meltemp apparatus and are uncorrected. Proton NMR spectra were obtained on Bruker 300 MHz or Varian 400 MHz spectrometer as solutions in CDCl 3 with Me 4 Si as an internal standard. The final compounds were, in general, hygroscopic solids. FAB mass spectra were run on a VG 70S mass spectrometer. Thin layer chromatography (TLC) of phosphocholines in CHCl 3 : MeOH : NH 4 OH (70 : 35 : 7) and CHCl 3 : MeOH (2 : 1) gave a single spot, which gave a blue colour with a modified Dittmer-Lester reagent (Ryu & MacCoss, 1979) . A representative synthetic procedure is given for INK-3; the remaining phosphocholines were prepared from the appropriate reagents using analogous procedures as those detailed below and in our previous papers (Piantadosi et al., 1991; Meyer et al., 1991; Morris-Natschke et al., 1993) . Complete high resolution mass spectra results are available as supplementary data from the Editor-in-Chief.
3-Dodecanamido-1,2-propanediol
3-Amino-1,2-propanediol (42 g, 0.47 mol) was dissolved in pyridine (150 ml) and DMF (200 ml). Dodecanoyl chloride (47 g, 0.46 mol) in 150 ml DMF was added dropwise. After 24 h at room temperature, the product was removed by filtration, washed with H 2 O and recrystallized from MeOH, then from CHCl 3 . The amide was obtained in 28% yield (34.7 g, 0.013 mol, m.p. 94-96°C). 1 H NMR (CDCl 3 ): 0.90 (t, 3H, terminal CH 3 ), 1.25 [m, 16H (CH 2 ) 8 ], 1.6 (m, 2H, NHCOCH 2 CH 2 ), 2.25 (t, 2H, NHCOCH 2 ), 3.45 (m, 2H, CH 2 NH), 3.6 (m, 2H, CH 2 OH), 3.8 (m, 1H, CHOH), 5.8 (t, 1H, NH).
3-Dodecanamido-1-triphenylmethoxy-2propanol
The above diol (5.5 g, 0.020 mol) was dissolved in dry pyridine (50 ml), then a solution of trityl chloride (5.6 g, 0.020 mol) in pyridine (50 ml) was added dropwise at 50°C. The reaction mixture was stirred at this temperature for 10 h and then cooled. The pyridine was removed under vacuum, and water (100 ml) was added to the solid residue. After filtration and washing, the crude product was partitioned between water and CHCl 3 . The water layer was extracted again with CHCl 3 and the organic layers combined and dried over anhydrous Na 2 SO 4 . After removing solvent, the resulting solid was dissolved in hexane : ethyl acetate (3 : 1); 1 g of starting diol was filtered. The mother liquor was concentrated and chromatographed on silica gel with a discontinuous gradient of hexane : EtOAc to give 7 g (0.014 mol, 70% yield) of pure product. 1 H NMR (CDCl 3 ): 0.90 (t, 3H, terminal CH 3 ), 1.25 [m, 16H (CH 2 ) 8 ], 1.6 (m, 2H, NHCOCH 2 CH 2 ), 2.2 (t, 2H, NHCOCH 2 ), 3.2-3.4 (overlapping m, 3H, CH 2 NH and CH a CH b OTr), 3.55 (m, 1H, CH a CH b Tr) 3.9 (m, 1H, CHOH), 5.7 (t, 1H, NH), 7.3-7.5 (m, 15H, aromatic H).
3-Dodecanamido-2-octyloxy-1-triphenylmethoxypropane
The synthesized trityl ether (7.0 g, 0.013 mol) in 30 ml dry THF was added dropwise to an ice-cooled suspension of sodium hydride (1.0 g of 60% oil dispersion, 0.025 mol) in 100 ml THF under nitrogen. After warming to room temperature, heat was applied (60°C) for 1 h. 1-Bromooctane (2.9 g, 0.015 mol, neat) was added dropwise and heating continued for 10 h. After cooling, ice and then water were added slowly. The biphasic system was separated and the water layer extracted with EtOAc (3×50 ml). All organic fractions were combined and dried over anhydrous Na 2 SO 4 . After removing solvent in vacuo, the residue was chromatographed with a gradient of hexane : EtOAc (100 : 0 to 6 : 1) to give 3.6 g (38% yield) of pure product. Impure product was rechromatographed using the same conditions to give an added 3.0 g (31% yield) of product as a viscous oil. 1 H NMR (CDCl 3 ): 0.85 (t, 6H, terminal CH 3 ), 1.25 [m, 26H (CH 2 ) 8 and (CH 2 ) 5 ], 1.45 (m, 4H, NHCOCH 2 CH 2 and OCH 2 CH 2 ), 2.2 (t, 2H, NHCOCH 2 ), 3.2-3.6 (overlapping m, 7H, CH 2 CHCH 2 , OCH 2 ), 5.75 (t, 1H, NH), 7.3-7.5 (m, 15H, aromatic H).
3-Dodecanamido-2-octyloxy-1-propanol
Detritylation of the above compound (6.0 g, 9.5 mmol) was accomplished using p-toluenesulphonic acid (0.6 g, 3.1 mmol) in CHCl 3 : MeOH (60 ml : 18 ml). The reaction mixture was stirred at room temperature for 24 h then saturated NaHCO 3 solution was added and stirred for 30 min. The layers were separated and the CHCl 3 fraction dried over anhydrous Na 2 SO 4 . After concentration in vacuo, the residue was purified twice by column chromatography using CHCl 3 : MeOH as eluent (100 : 0 and 15 : 1) to give 3.0 g (80% yield) of pure 3-dodecanamido-2-octyloxy-1propanol (m.p. 42-43°C). 1 H NMR (CDCl 3 ): 0.9 (t, 6H, terminal CH 3 ), 1.25 [m, 26H (CH 2 ) 8 and (CH 2 ) 5 ], 1.6 (m, 4H, NHCOCH 2 CH 2 and OCH 2 CH 2 ), 2.2 (t, 2H, NHCOCH 2 ), 3.2-3.7 (overlapping m, 7H, CH 2 CHCH 2 , OCH 2 ), 5.75 (t, 1H, NH).
3-Dodecanamido-2-octyloxypropyl 2-bromoethyl phosphate
3-Dodecanamido-2-octyloxy-1-propanol (1.0 g, 2.6 mmol) in 60 ml 2 : 1 anhydrous Et 2 O : THF was cooled to 0°C. Pyridine (3.3 g) then 2-bromoethyl dichlorophosphate (2.4 g, 0.010 mol, prepared as described by Hansen et al., 1992) were added dropwise. After warming to room temperature, the mixture was refluxed for 4 h, cooled and water (10 ml) added. After stirring for 30 min, the solvent was removed in vacuo and the residue dissolved in 100 ml CHCl 3 : MeOH (2 : 1). The solution was extracted with water and backextracted with 2×50 ml 2 : 1 CHCl 3 : MeOH. The combined organic fractions were dried over anhydrous Na 2 SO 4 , evaporated and chromatographed on silica gel using a gradient of CHCl 3 : MeOH (100 : 1 to 15 : 1). The desired bromoethylphosphate (633 mg, 1.1 mmol) was obtained in 43% yield. 1 H NMR (CDCl 3 ): 0.85 (t, 6H, terminal CH 3 ), 1.25 [m, 26H (CH 2 ) 8 and (CH 2 ) 5 ], 1.55 (m, 4H, NHCOCH 2 CH 2 and OCH 2 CH 2 ), 2.3 (t, 2H, COCH 2 ), 3.4-3.7 (overlapping m, 7H, CHCH 2 NHCO, CH 2 Br, OCH 2 ), 3.85 and 4.25 (two m, 4H, CH 2 OPO 3 CH 2 ), 6.8 (m, 1H, NH).
3-Dodecanamido-2-octyloxypropyl phosphocholine (INK-3)
The above phosphate ester (633 mg, 1.1 mmol) in 52 ml CHCl 3 : isopropanol : DMF (5 : 3 : 5) was reacted with aqueous Me 3 N (7.6 ml) at 65°C for 5 h. After cooling, Ag 2 CO 3 (380 mg) was added and the heat reapplied for 1 h. After filtering the precipitated AgBr, the solvent was removed in vacuo and the residue purified by chromatography on silica gel using CHCl 3 : MeOH (10 : 1 to 2 : 1) followed by CHCl 3 : MeOH : NH 4 OH (75 : 25 : 5) to give 275 mg pure (46% yield) and 140 mg impure phosphocholine. FAB MS showed a [MH] + ion at 551.418345 (C 28 H 60 N 2 O 9 P, 1.0 p.p.m.). 1 H NMR (CDCl 3 ): 0.87 (t, 6H, terminal CH 3 ), 1.25 [m, 26H (CH 2 ) 8 (CH 2 ) 5 ], 1.5 (m, 4H, NHCOCH 2 CH 2 , OCH 2 CH 2 ), 2.2 (t, 2H, COCH 2 ), 3.3 [s, 9H, N(CH 3 ) 3 ], 3.3-3.8 (overlapping m, 5H, CH 2 CHOCH 2 ) (3.8-3.9, overlapping m, 4H, CH 2 OP, CH 2 NMe 3 ), 4.4 (m, 2H, PO 3 CH 2 ), 7.0 (m, 1H, NH).
3-Dodecanamido-2-octyloxypropyl diphenyl phosphate
Diphenylchlorophosphate (0.4 ml, 1.7 mmol) in 10 ml diethyl ether was cooled to 4°C under nitrogen. 3-Dodecanamido-2-octyloxy-1-propanol (500 mg, 1.3 mmol) in 8 ml pyridine and 10 ml Et 2 O was added dropwise. The solution was warmed to room temperature, then heated to around 52°C for 4 h and cooled to room temperature, diluted with 30 ml Et 2 O, washed with 15 ml portions of water, 0.5 M HCl and water. The organic layer was dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo to an oil. Chromatography with a gradient of hexane : EtOAc (10 : 1 to 3 : 1) gave 556 mg (0.9 mmol, 69%) of pure product. 1 H NMR (CDCl 3 ): 0.9 (t, 6H, terminal CH 3 ), 1.25 [m, 26H (CH 2 ) 8 and (CH 2 ) 5 ], 1.55 (m, 4H, NHCOCH 2 CH 2 and OCH 2 CH 2 ), 2.3 (t, 2H, COCH 2 ), 3.3-3.7 (overlapping m, 5H, OCH 2 , CHCH 2 NHCO), 4.25 (m, 2H, CH 2 OP), 5.9 (m, 1H, NH), 7.2-7.8 (m, 10H, aromatic H).
3-Dodecanamido-2-octyloxypropyl phosphatidic acid
PtO 2 (81 mg) was placed in a Parr hydrogenation bottle. 3-Dodecanamido-2-octyloxypropyl diphenyl phosphate (589 mg, 1.0 mmol) in 118 ml EtOH was then added. After hydrogenation at 158.5 kPa (23 p.s.i.) for 4.5 h, the reaction mixture was filtered and checked for completion by TLC. To ensure complete conversion to the phosphatidic acid, hydrogenation was continued for another 6 h using 120 mg of fresh catalyst. The reaction mixture was then filtered through Celite and the EtOH removed in vacuo. The residue was chromatographed on silica gel using 4 : 1 CHCl 3 : MeOH as eluent to obtain 233 mg (0.54 mmol, 54% yield) of pure phosphatidic acid. 1 H NMR (CDCl 3 ): 0.9 (t, 6H, terminal CH 3 ), 1.25 [m, 26H (CH 2 ) 8 and (CH 2 ) 5 ], 1.55 (m, 4H, NHCOCH 2 CH 2 and OCH 2 CH 2 ), 2.3 (t, 2H, COCH 2 ), 3.3-3.7 (overlapping m, 5H, OCH 2, CHCH 2 NHCO), 4.0 (m, 2H, CH 2 OP), 6.8 (m, 1H, NH).
The procedure of Piantadosi et al. (1991) was followed to synthesize INK-14 in 22% yield from the above phosphatidic acid and AZT. FAB MS showed a [MH+Na] + ion at 737.403800 (C 33 H 59 N 6 O 9 PNa, -8.0 p.p.m.). 1 H NMR (CDCl 3 ): 0.9 (t, 6H, terminal CH 3 ), 1.25 [m, 26H (CH 2 ) 8 and (CH 2 ) 5 ], 1.55 (m, 4H, NHCOCH 2 CH 2 and OCH 2 CH 2 ), 1.8 (s, 3H, thymine CH 3 ), 2.2 (t, 2H, COCH 2 ), 2.3-2.55 (m, 2H, 2′-CH 2 ), 3.3-3.6 (overlapping m, 5H, OCH 2 , CHCH 2 NHCO), 3.8-4.2 (overlapping m, 5H, CH 2 OPO 3 CH 2 , 4′-CH), 4.5 (1H, 3′-CH), 6.15 (m, 1′-CH), 7.4 (m, 1H, thymine CH).
Materials and Methods: Virology

Virus stocks
HIV-1 (strain IIIB) was propagated in H9IIIB cells as previously described (Krugner-Higby et al., 1995) . Stocks of HIV-2 from R Weiss (Institute of Cancer Research, London, UK), TIBO-resistant HIV-1 (RT mutant at codons 103 and 181) from E Emini (Merck, Sharp & Dohme Research Laboratories, West Point, Pa., USA) and AZT-resistant HIV-1 isolates 1073 (RT mutant at codons 70 and 215) and 1074 (RT mutant at codons 70 and 215), and matched pairs of AZT-sensitive and AZT-resistant HIV-1 clinical isolates G-762 (wild-type), G-691 (RT mutant) and H112-2 (wild-type), G-910 (RT mutant at codon 215) from D Richman (University of California, La Jolla, Calif., USA) were obtained through the AIDS Research and Reference Reagent Program (Division of AIDS Program, NIH, Bethesda, Md., USA). Stocks of viruses were propagated in acutely infected CEM-SS cells as previously described (Krugner-Higby et al., 1995) .
Cell cultures
All primary peripheral blood leukocytes (PBL) and cell lines were incubated and maintained in RPMI 1640 medium supplemented with penicillin (100 U/ml), streptomycin (100 µg/ml), 2 mM L-glutamine and 20% fetal bovine serum (growth medium) as previously described (Krugner-Higby et al., 1995) . PBL were obtained from HIV-1-seronegative male and female personnel in the laboratory. Whole blood was separated into PBL using Isolymph (Gallard-Schlesinger Industries, Carle Place, N.Y., USA) according to a protocol supplied by the manufacturer. The separated PBL were activated for 3 days in the presence of phytohaemagglutinin (PHA; 5 µg/ml in growth medium), washed in growth medium, treated with polybrene (5 µg/ml in growth medium) and infected with HIV-1 in the presence of polybrene (1 µg/ml in growth medium). After a 2 h virus attachment, the cells were washed with growth medium to remove unattached HIV-1 and incubated (1×10 6 cells/ml of growth medium) for 96 h with or without added test compounds. Supernatant medium was harvested to measure virus replication by reverse transcriptase (RT) activity (Krugner-Higby et al., 1995) .
TC 50 determinations
To measure the cytotoxicity in CEM-SS cells, test compounds were dissolved in 95% ethanol, methanol : chloroform (1 : 1) or RPMI 1640 plus 20% FBS growth medium, diluted in log 10 or 0.5 log 10 series in growth medium and tested for cytotoxicity in triplicate wells containing 10 000 CEM-SS cells/well of a 96-well plate. A viable cell count was made prior to the test to ensure more than 90% cell viability. Log phase cells were treated with test compound for 48 h at 37°C (approximately 2.5 cell generations in untreated control cultures) and pulselabelled with 1 µCi [ 3 H]TdR (sp. act. 20 Ci/mmol) for 6 h before harvesting the cells using a multichannel cell harvester to measure total DNA synthesis in the presence or absence of compound. To measure cytotoxicity in PBL, the cells were activated with PHA (5 µg/ml) for 72 h, washed to remove the PHA and 20 000 activated PBL cells/well were cultured for 96 h in growth medium with or without test compound as described for CEM-SS cells. The treated PBL cells were labelled with 0.1 µCi [ 3 H]TdR (sp. act. 20 Ci/mmol) during the final 24 h culture period before harvesting. From the data, a TC 50 for cytotoxicity was calculated as previously described by Chou and coworkers (Chou & Talalay, 1987; Johnson et al., 1989) as cited by Piantadosi et al. (1991) .
Syncytium plaque assay
The syncytium plaque assay for infectious virus multiplication was done in the presence or absence of PC lipid or lipid-AZT conjugate as previously described by us (Kucera et al., 1990a) . The syncytium plaques were counted on day 5 or 6 post-infection and treatment and the percentage inhibition and effective concentration 50 (EC 50 ) were calculated by the method of Chou and coworkers (Chou & Talalay, 1987; Johnson et al., 1989) as cited by Piantadosi et al. (1991) .
Fusogenic assay
Persistently HIV-1-infected H9IIIB cells were treated with compound for 96 h and cocultured with uninfected CD4 + CEM-SS cells (ratio 1 : 100) in the presence of added compound for 48 h. The number of fusogenic cells was counted relative to untreated control cells to determine the percentage inhibition of fusogenic cells. The EC 50 values were calculated by the method cited by Piantadosi et al. (1991) .
Colony forming units-granulocyte macrophage (CFU-GM) assay
Mouse bone marrow granulocyte/macrophage cells were harvested and suspended in soft agar medium with or without added test compound (Herrmann DBJ, Kucera LS, Zilch H, Mertens A & Opitz HG; BM21.1290: invitro evaluation of a potential new anti-AIDS compound; XIth International Conference on AIDS, July 7-12 1996, Vancouver, Canada, Abstract p64). After incubation, the number of cell colonies was counted to determine the percentage inhibition of colony formation relative to a mock (PBS)-treated control. The 50% toxic concentration (TC 50 ) was calculated by the method cited by Piantadosi et al. (1991) .
Results
Chemistry
Phospholipid and lipid-AZT conjugates were synthesized in our laboratories as previously described (Piantadosi et al., 1991) . Briefly, 3-amino-1,2-propanediol was reacted with an acyl chloride to form an alkylamidopropanediol. The primary alcohol was protected as the trityl ether by reaction with trityl chloride, then the secondary alcohol was alkylated with the appropriate alkyl halide using sodium hydride as the base. After removing the trityl ether with p-toluenesulphonic acid, the hydroxy group was converted either to a phosphocholine [reaction first with bromoethyl phosphodichloridate (Hansen et al., 1982) then with aqueous trimethyl amine] or, in the case of INK-14, to the phosphatidic acid (reaction with diphenyl chlorophosphate then catalytic hydrogenolysis over PtO 2 ). The phosphatidic acid was coupled with AZT using dicyclohexylphosphodiimide as the condensing agent.
Evaluation of compounds for cytotoxicity and anti-HIV-1 activity
To optimize the activity and/or SI, PC lipid and lipid-AZT conjugate compounds varying in hydrocarbon chain lengths at position 1 or 2 were synthesized (Table 1) and evaluated for cytotoxicity, anti-HIV-1 activity and SI in CEM-SS and PBL cells. Results of these experiments (Table 2) Table 2) . Compounds with a 12 or 10 carbon chain length at position 1, an 8 or 12 carbon chain length at position 2, and phosphocholine at position 3 of the three carbon backbone (INK-3 or INK-15) gave the highest SI (298.9 and 389.0, respectively) among the PC lipid compounds. INK-14, which has the same hydrocarbon chain lengths at position 1 and position 2 as INK-3 but is linked at position 3 through a phosphate ester bond to AZT in place of phosphocholine (see Table 1 ), gave the highest SI (>1250) To determine the EC 50 , three to five serial concentrations of each compound were assayed in duplicate. The syncytial plaque assay was used with CEM-SS cells infected with the prototype of HIV-1 (strain H9IIIB). A reverse transcriptase assay was used with PBL cells infected with a clinical isolate of HIV-1 (strain H112-2) as cited in Kucera et al. (1990a) . †TC 50 and EC 50 values were calculated by the method of Chou and coworkers (Chou & Talalay, 1987; Johnson et al., 1989) as cited by Piantadosi et al. (1991) . ‡SI is the ratio TC 50 /EC 50 . §Data from Piantadosi et al. (1991) .
among all the compounds evaluated. In PBL cells, the TC 50 values were comparable to those from CEM-SS cells. However, the EC 50 values were consistently higher in PBL than in CEM-SS cells ( Table 2) . These results were most likely due to differences in sensitivity of prototype HIV-1 (strain H9IIIB) and a clinical isolate (strain H112-2) to the test compounds.
Inhibition of HIV-2 and TIBO-and AZT-resistant HIV-1 strains as measured by syncytial plaque assay
Since selected PC lipid compounds (for example INK-3 and CP-51) have potent activity against prototype strains of HIV-1, we extended evaluation of their activity against HIV-2 and TIBO-and AZT-resistant HIV-1 clinical isolates. Results (Table 3) indicated that both INK-3 and CP-51 gave dose-dependent activity against HIV-2, with EC 50 values of 0.21 and 0.32 µM and against TIBO-resistant HIV-1 with EC 50 values of 0.11 and 0.10 µM, respectively. The EC 50 values for INK-3 and CP-51 against AZT-resistant HIV-1 clinical isolates (1073, 1074, G910, G691) ranged from 0.12 to 0.90 µM and 0.19 to 0.64 µM, respectively ( Table 3 ). The EC 50 values for AZT against the same AZT-resistant HIV-1 clinical isolates ranged from 0.03 to >2.5 µM (Table 3 ). Note that the EC 50 for AZT against a sensitive prototype HIV-1 strain was 0.009 µM (Table 2 ). Other results indicated that the PC lipid INK-15 had no significant fold increase in EC 50 between the matched pairs of AZT-sensitive and AZT-resistant HIV-1 clinical isolates (Table 4 ). However, the lipid-AZT conjugate INK-14 and AZT alone showed a significant fold increase in the EC 50 ratio between the AZT-sensitive and AZT-resistant HIV-1 clinical isolates of 23.4, 469 and 673.3, 75, respectively. In summary, the PC lipids INK-3 and CP-51 have potent activity against HIV-2 and TIBOand AZT-resistant HIV-1. There is no apparent crossresistance between PC lipid and TIBO or AZT compounds. In contrast, the lipid-AZT conjugate (INK-14) did show some cross-resistance with AZT.
Inhibition of fusogenic activity between persistently HIV-1-infected H9IIIB cells and uninfected CD4 + CEM-SS cells
Published data from our laboratories indicated that CP-51 significantly inhibited HIV-1-induced fusogenic activity (Krugner-Higby et al., 1995) . In similar experiments (Table  5) , results indicated that INK-3 also has significant dosedependent activity against HIV-1-induced fusogenic activity. The EC 50 values were 0.08, 0.18 and >1.0 µM for INK-2, -3, and -1, respectively (Table 5 ). These results suggest that selected PC lipid compounds active against infectious HIV production ( Table 2) also inhibited virusinduced fusogenic activity.
Toxicity against mouse bone marrow cells as compared to AZT
Two independent experiments were designed to compare the relative toxicity of CP-51 and selected INK compounds with AZT. Results of these studies indicated that INK-2, -3 and -6 had a TC 50 value of >100 µg/ml (Table 6 ). In two experiments, the TC 50 values for CP-51 were 9.15 and 14.17 µg/ml compared to 0.142 and 0.259 µg/ml for AZT (Table 6 ). These data are interpreted to suggest that selected PC lipid compounds are significantly less cytotoxic than AZT to mouse bone marrow cells.
Discussion
Most of our previously synthesized alkylamidopropyl phosphocholines and alkoxy-and alkylthioglycerol phosphocholines (PC lipids) were analogues of phosphatidylcholine and contained a long hydrocarbon chain length (C16-C18) at position 1 and a short chain length (C1-C2) at position 2 of the three carbon backbone. Many of these compounds exhibited potent anti-HIV-1 activity. The most promising analogue we have reported to date (Chou & Talalay, 1987; Johnson et al., 1989) as cited by Piantadosi et al. (1991) . (Kucera et al., 1990a ) was 1-octadecanamido-2ethoxypropyl-3-phosphocholine (CP-51). This amidoalkyl derivative exhibited an EC 50 of 0.11 µM and a SI of 130 (Table 2) . Accordingly, we chose this analogue as our lead compound and proceeded to modify its structure to optimize its anti-HIV-1 inhibitory activity and/or SI. In addition, we wanted to ascertain whether a long hydrocarbon chain length at position 1 was essential for optimum anti-HIV-1 selectivity. As seen from data in Table 2 , numerous synthetic CP-51 analogues including INK-2, INK-3, INK-6 and INK-15 exhibited a higher SI than CP-51. The SI values for these analogues in CEM-SS cells were 184.0, 298.9, 191.4 and 389.0, respectively, whereas their EC 50 values were comparable to that of CP-51. These results demonstrated that a long hydrocarbon chain length of 16-18 carbons is not essential for optimum selectivity in this series of PC compounds. Notably, data presented in Table  2 suggested that a shorter hydrocarbon chain length (Table  1) at position 1 (10 or 12 carbons) and a longer chain at position 2 (12 or 8 carbons) as seen in INK-15 and INK-3, respectively, improved the SI up to threefold (with a concomitant decrease in cytotoxicity) compared with the 18 and 2 hydrocarbon chain lengths in CP-51.
Previously, we synthesized a series of alkyletherglycerol phosphocholines (Meyer et al., 1991) . Like the alkylamido phosphocholine CP-51, these alkylether compounds had a long hydrocarbon chain (C16-C18, oxy-or thioether) at position 1 and a short chain (methoxy or ethoxy) at position 2. The EC 50 values for these alkylether phosphocholines ranged from 0.3 to 1.4 µM and their SI were lower (4 to 69) compared to that of . In view of the above data with the INK compounds, it was of interest to synthesize an alkylether analogue of INK-2 to determine whether the SI could be similarly improved in this series. This alkylether analogue, INK-4, with oxyether hydrocarbon chain lengths of 12 and 10 at the 1 and 2 positions, respectively, exhibited an EC 50 of 0.64 µM, a TC 50 of 75.7 µM, and a SI of 118.3. Notably, the TC 50 value is significantly different from that of any previously reported alkylether phosphocholine (3 to 19 µM; Meyer et al., 1991) , again demonstrating that such hydrodrocarbon chain length modifications will lead to a less cytotoxic compound. In summary, these data indicated that hydrocarbon chain lengths in the range of 10 to 12 at position 1 and 8 to 12 at position 2 should result in compounds with less cytotoxicity than those with 16 to 18 hydrocarbon chain lengths at position 1 and 1 to 2 at position 2.
Also, the TC 50 values from PBL cells were comparable to those from CEM-SS cells ( Table 2) . INK-13 and INK-14, with 8 and 10 carbons at position 1 and 7 carbons at position 2, respectively, were the least cytotoxic (TC 50 ≥100 µM) compounds in the series. At the present time, no specific experiments have been done to determine why INK-13 and INK-14 were the least cytotoxic in the series of compounds evaluated. In the case of the conjugate INK-14, the hypothesis is that the lipid component acts as a carrier for AZT. The lipid anchors the conjugate into the cell membrane and is metabolized to slowly release lower concentrations of AZT into cells compared to AZT treatment alone. The end result is reduced toxicity from AZT. Evidence in support of this hypothesis is the lower TC 50 and higher SI for INK-14 compared to AZT (Table 2 ).
In the case of the phospholipid-AZT conjugates, INK-14 [3′-azido-3′-deoxy-5′-(3-dodecylamido-2-octoxypropyl)-phosphothymidine] and CP-92 [3′-azido-3′-deoxy-5′-(3-octadecylamido-2-ethoxypropyl)-phosphothymidine] had comparable SI values [>1250 (Table 2) and 1793 (Piantadosi et al., 1991) , respectively]. Both compounds had a higher SI than AZT alone (411, Table 2 ) and were three-to fourfold more selective than AZT. In addition, the cytotoxicity was lower; the TC 50 for INK-14 was >100 µM in comparison to 3.7 µM for AZT. Persistently HIV-1-infected H9IIIB cells were treated with compound for 96 h and cocultured with uninfected CD4 + CEM-SS cells (ratio 1 : 100) in the presence of added compound for 48 h. The number of fused cells was counted relative to untreated control cells to determine the percentage inhibition of fusion and the IC 50 . The IC 50 values were calculated by the method of Chou and coworkers (Chou & Talalay, 1987; Johnson et al., 1989) as cited by Piantadosi et al. (1991) . selective activity against HIV-1 and HIV-2 as well as against TIBO-and AZT-resistant strains of HIV-1 and virus-induced cell fusion. In view of the markedly reduced toxicity of PC lipid analogues against bone marrow cell growth in vitro compared to AZT, PC lipid analogues offer an innovative approach toward development of novel strategies for the treatment of HIV infections and AIDS.
